Data gathered: November 30
Alternative Data for Virpax Pharmaceuticals
| Alternative Data | Value | 3m Change | Trend | Benchmark |
|---|---|---|---|---|
| Job Posts | N/A | Sign up | Sign up | Sign up |
| Sentiment | 81 | Sign up | Sign up | Sign up |
| Webpage traffic | 1,000 | Sign up | Sign up | Sign up |
| Google Trends | N/A | Sign up | Sign up | Sign up |
| 4chan Mentions | N/A | Sign up | Sign up | Sign up |
| Reddit Mentions | N/A | Sign up | Sign up | Sign up |
| Stocktwits Mentions | 12 | Sign up | Sign up | Sign up |
| Stocktwits Subscribers | 6,114 | Sign up | Sign up | Sign up |
| Twitter Followers | 3,403 | Sign up | Sign up | Sign up |
| Twitter Mentions | 16 | Sign up | Sign up | Sign up |
| News Mentions | N/A | Sign up | Sign up | Sign up |
| Customer reviews | N/A | Sign up | Sign up | Sign up |
| Linkedin Employees | 10 | Sign up | Sign up | Sign up |
About Virpax Pharmaceuticals
Virpax Pharmaceuticals, Inc., a preclinical-stage pharmaceutical company, develops various drug-delivery systems and drug-releasing technologies focused on advancing non-opioid and non-addictive pain management treatments and treatments for central nervous system disorders.
| Price | $0.46 |
| Target Price | Sign up |
| Volume | 830,540 |
| Market Cap | $3M |
| Year Range | $0.44 - $4.26 |
| Dividend Yield | 0% |
| Analyst Rating | 0% buy |
| Industry | Biotechnology |
In the news
 |
Virpax Pharmaceuticals Regains Compliance with Nasdaq Listing Requirements and Makes Key AppointmentsNovember 24 - ETF Daily News |
 |
Why Is Virpax Pharmaceuticals Stock Gaining On Friday?November 22 - Biztoc.com |
Spartan Capital Securities, LLC Serves as Sole Placement Agent in Virpax Pharmaceuticals, Inc.'s $5.0 Million Public OfferingNovember 18 - GlobeNewswire |
|
 |
Virpax Pharmaceuticals, Inc. Announces Closing of $5.0 Million Public Offering of Common Stock and Pre-Funded WarrantsNovember 15 - Yahoo |
|
Virpax Pharmaceuticals, Inc. Announces Pricing of $5.0 Million Public Offering of Common Stock and Pre-Funded WarrantsNovember 12 - Yahoo |
 |
Virpax Pharmaceuticals (NASDAQ:VRPX) & UroGen Pharma (NASDAQ:URGN) Critical ContrastNovember 10 - ETF Daily News |
Financial performance View All
| Revenue | Cost of Revenue | Gross Profit | Net Income | ebitda | EPS | |
|---|---|---|---|---|---|---|
| Q3 '24 | 0 | 780,000 | -780,000 | -2M | -1.9M | -0.431 |
| Q2 '24 | 0 | 1.5M | -1.5M | -3.5M | -3.5M | -1.750 |
| Q1 '24 | 0 | 1.7M | -1.7M | -3.2M | -3.3M | -2.750 |
| Q4 '23 | 0 | 3.4M | -3.8M | -4.6M | -4.6M | -3.900 |
| Q3 '23 | 120,000 | 6.6M | -6.5M | -6M | -6.1M | -0.510 |
Insider Transactions View All
| Sendrow Jerrold filed to buy 9,006 shares at $1.3. May 26 '22 |
| Floyd Eric filed to buy 8,018 shares at $1.4. May 20 '22 |
| Mack Anthony P. filed to buy 252,562 shares at $1.3. May 20 '22 |
Similar companies
Read more about Virpax Pharmaceuticals (VRPX) and their ai stock analysis, price prediction, earnings, congress trading, insider transactions, technical analysis, job posts, sentiment, webpage traffic, google trends, 4chan mentions, reddit mentions, stocktwits mentions, stocktwits subscribers, twitter followers, twitter mentions, news mentions, customer reviews & linkedin employees.
What is the Market Cap of Virpax Pharmaceuticals?
The Market Cap of Virpax Pharmaceuticals is $3M.
What is the current stock price of Virpax Pharmaceuticals?
Currently, the price of one share of Virpax Pharmaceuticals stock is $0.46.
How can I analyze the VRPX stock price chart for investment decisions?
The VRPX stock price chart above provides a comprehensive visual representation of Virpax Pharmaceuticals' stock performance over time. Investors can use this chart to identify patterns, trends, and potential support or resistance levels. By examining historical data and recent price movements, investors can make more informed decisions regarding buying, holding, or selling Virpax Pharmaceuticals shares. Our platform offers an up-to-date VRPX stock price chart, along with technical data analysis and alternative data insights.
Does VRPX offer dividends to its shareholders?
As of our latest update, Virpax Pharmaceuticals (VRPX) does not offer dividends to its shareholders. Investors interested in Virpax Pharmaceuticals should consider the potential for capital appreciation as the primary return on investment, rather than expecting dividend payouts.
What are some of the similar stocks of Virpax Pharmaceuticals?
Some of the similar stocks of Virpax Pharmaceuticals are Amgen, Gilead Sciences, Catalyst Pharmaceuticals, Inovio Pharmaceuticals, and Anavex Life Sciences.
.